MSH2 and female reproductive organ cancer: Recently, a report from the Prospective LS Database showed that at age 75 years, gynecologic cancers were more prevalent than CRC in MSH2, MSH6, and PMS2 mutation carriers, with cumulative incidence rates of 53.3%, 49.6%, and 23.3%, respectively [10].